Literature DB >> 18837013

On the prediction of hepatic clearance using the diluted plasma in metabolic stability assay.

Leonid M Berezhkovskiy1, S Cyrus Khojasteh, Jason S Halladay, Cornelis E C A Hop.   

Abstract

It was suggested that in vivo hepatic clearance, CL(h), may be predicted rather accurately with the in vitro values of intrinsic clearance, CL(int), obtained using the microsomal incubation mix containing diluted plasma, and consequently calculated by the well-stirred model equation. Conceivably the improvement could be due to the direct account of plasma protein binding in the measured values of CL(int). It is shown in this article that the prediction of CL(h) done in this manner may not yield accurate results, both substantial underestimation or overestimation of the true value is possible. The procedure may be useful to reduce the overestimation of CL(h) for highly protein bound drugs, though the obtained value of CL(h) may be far off from the correctly calculated one. The accurate way of calculating CL(h), based on the value of CL(int) obtained in diluted plasma, is presented. It takes into account both the drug protein binding in diluted plasma and microsomal binding, as well as blood-plasma concentration ratio. The prediction of CL(h) by the suggested calculation using the experimental data on CL(int), measured at different plasma dilutions for several drugs, yields consistent (dilution independent) values of hepatic clearance. It does not seem possible to avoid the measurement of plasma protein binding, microsomal binding and blood-plasma concentration ratio for an accurate and consistent prediction of CL(h), even if the value of CL(int) were obtained in the pure (undiluted) plasma. In an early stage screening using plasma in the microsomal incubation mix may be beneficial for fast metabolizing drugs with relatively high protein binding. This would reduce a possible overestimation CL(h), and also lead to the increase of the half-life in the microsomal incubation, so that it could be measured more accurately. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18837013     DOI: 10.1002/jps.21582

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

1.  On the maintenance of hepatocyte intracellular pH 7.0 in the in-vitro metabolic stability assay.

Authors:  Leonid M Berezhkovskiy; Susan Wong; Jason S Halladay
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-11-01       Impact factor: 2.745

Review 2.  Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates.

Authors:  T J Maguire; E Novik; P Chao; J Barminko; Y Nahmias; M L Yarmush; K-C Cheng
Journal:  Curr Drug Metab       Date:  2009-12       Impact factor: 3.731

3.  Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery.

Authors:  Doha Naga; Neil Parrott; Gerhard F Ecker; Andrés Olivares-Morales
Journal:  Mol Pharm       Date:  2022-04-27       Impact factor: 5.364

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.